Selegiline Hydrochloride NDC 73141-006

NDC codes

FDA NDC Directory

Product NDC (as listed)73141-006Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73141-0006Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73141-006-02	73141000602	60 TABLET in 1 BOTTLE (73141-006-02)Marketed from Mar 15, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Selegiline Hydrochloride
Generic name (nonproprietary): selegiline hydrochloride
Active ingredients: Selegiline hydrochloride — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: A2A Integrated Pharmaceuticals
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074672
Marketing start: Mar 15, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)Monoamine Oxidase-B Inhibitors (Mechanism)
Identifiers: Product ID 73141-006_339f9a9e-dffc-daac-e063-6294a90ae1feSPL ID 339f9a9e-dffc-daac-e063-6294a90ae1feSPL set ID a59ff47b-4379-44f3-9d2c-f8c6121d1881RxCUI 859193UNII 6W731X367QUPC 0373141006027
Pharmacologic class: Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473141000602 followed by a unit qualifier and the quantity

Package 73141-0006-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 28, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Selegiline Hydrochloride Tablets, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 074672

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 074672
Product	Strength	Form · route	Labeler	Product NDC
Selegiline Hydrochloride	Selegiline hydrochloride 5 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-006